Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Lefebvre, Eric ^a   Moyle, Graeme ^b   Reshef, Ran ^c   Richman, Lee P ^d   Thompson, Melanie ^e   Hong, Feng ^f   Chou, Hsin L ^f   Hashiguchi, Taishi ^g   Plato, Craig ^h   Poulin, Dominic ⁱ   Richards, Toni ^h   Yoneyama, Hiroyuki ^g   Jenkins, Helen ^a   Wolfgang, Grushenka ^j   Friedman, Scott L ^f  

^a Tobira Therapeutics Inc   (United States)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e AIDS Research Consortium of Atlanta   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g Stelic Institute of Regenerative Medicine   (Japan)

^h Plato BioPharma   (United States)

ⁱ CHARLES RIVER LABORATORIES   (United States)

^j Independent Consultant ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CENICRIVIROC; COLLAGEN; COLLAGEN TYPE 1; DEXAMETHASONE; MESSENGER RNA; THIOACETAMIDE; THIOGLYCOLIC ACID; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; IMIDAZOLE DERIVATIVE; TAK-652;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELL MIGRATION; CONTROLLED STUDY; DISEASE ACTIVITY; GENE EXPRESSION; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY MASS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER WEIGHT; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERITONITIS; PROTEIN EXPRESSION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMOTAXIS; DRUG EFFECTS; FIBROSIS; KIDNEY DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CCR5 RECEPTOR ANTAGONISTS; CHEMOTAXIS; FIBROSIS; IMIDAZOLES; KIDNEY DISEASES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CCR2;

EID: 84977139510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158156     Document Type: Article

References (56)

1. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015; 64: 830-841. doi: 10.1136/gutjnl-2014-306842 PMID: 25681399
2. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008; 12: 733-746. doi: 10.1016/j.cld.2008.07.007 PMID: 18984463
3. Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl. 2014; 4: 2-8.
4. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382: 260-272. doi: 10.1016/S0140-6736(13)60687-X PMID: 23727169
5. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2012; 61: 416-426. doi: 10.1136/gutjnl-2011-300304 PMID: 21813474
6. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014; 60: 1090-1096. doi: 10.1016/j.jhep.2013.12.025 PMID: 24412603
7. Pradere JP, Kluwe J, De Minicis S, Jiao JJ, Gwak GY, Dapito DH, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013; 58: 1461-1473. doi: 10.1002/hep.26429 PMID: 23553591
8. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology. 2007; 132: 1937-1946. PMID: 17484886
9. Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physiol. 2012; 3: 213. doi: 10.3389/fphys.2012.00213 PMID: 22723782
10. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009; 119: 1858-1870. PMID: 19603542
11. Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009; 50: 185-197. doi: 10.1002/hep.22952 PMID: 19441102
12. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets. 2011; 10: 509-536. PMID: 22150762
13. Mitchell C, Couton D, Couty JP, Anson M, Crain AM, Bizet V, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol. 2009; 174: 1766-1775. doi: 10.2353/ajpath.2009.080632 PMID: 19359521
14. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes non-alcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012; 302: G1310-G1321. doi: 10.1152/ajpgi.00365.2011 PMID: 22442158
15. Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010; 120: 4129-4140. doi: 10.1172/JCI41732 PMID: 20978355
16. Kang YS, Lee MH, Song HK, Ko GJ, Kwon OS, Lim TK, et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int. 2010; 78: 883-894. doi: 10.1038/ki.2010.263 PMID: 20686445
17. Panzer U, Steinmetz OM, Stahl RA, Wolf G. Kidney diseases and chemokines. Curr Drug Targets. 2006; 7: 65-80. PMID: 16454700
18. Segerer S, Mac K M, Regele H, Kerjaschki D, Schlöndorff D. Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int. 1999; 56: 52-64. PMID: 10411679
19. Vielhauer V, Anders HJ, MacK M, Cihak J, Strutz F, Stangassinger M, et al. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J Am Soc Nephrol. 2001; 12: 1173-1187. PMID: 11373340
20. Xia Y, Entman ML, Wang Y. CCR2 regulates the uptake of bone marrow-derived fibroblasts in renal fibrosis. PLoS One. 2013; 8: e77493. doi: 10.1371/journal.pone.0077493 PMID: 24130892
21. Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011; 57: 118-125. doi: 10.1097/QAI.0b013e318213c2c0 PMID: 21317794
22. Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients. Antimicrob Agents Chemother. 2011; 55: 2768-2774. doi: 10.1128/AAC.00713-10 PMID: 21486960
23. Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005; 49: 4584-4591. PMID: 16251299
24. Kuroshima,K, Inanami M, Kanzaki N, Takeda Chemical Industries, Ltd. Receptor binding properties of TAK-652, a small molecular weight CCR5 antagonist (Report No. TAK-652/00045). 2003.
25. Lefebvre E, Gottwald M, Lasseter K, Chang W, Willett M, Smith PF, et al. Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. Clin Transl Sci. 2016; 9: 139-148. doi: 10.1111/cts.12397 PMID: 27169903
26. Thompson M, Saag M, Dejesus E, Gathe J, Lalezari J, Landay AL, et al. A 48-week randomized Phase 2b study evaluating cenicriviroc vs. efavirenz in treatment-naive HIV-infected adults with CCR5-tropic virus. AIDS. 2016; 30: 869-878. doi: 10.1097/QAD.0000000000000988 PMID: 26636929
27. Friedman SL, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016; 47: 356-365. doi: 10.1016/j.cct.2016.02.012 PMID: 26944023
28. Jalbert E, Byron MM, Shikuma C, Jenkins H, Lefebvre E, Barbour JD. Cenicriviroc achieves high CCR5 receptor occupancy at low nanomolar concentrations. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3; Boston, MA, USA. 530.
29. Byron MM, D'Antoni ML, Premeaux T, Lefebvre E, Ndhlovu LC. Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes. Presented at: Immunology 2015™ - The American Association of Immunologists (AAI) Annual Meeting; 2015 May 11; New Orleans, LA, USA.
30. Tobira Therapeutics, Inc., Ndhlovu Laboratory. In Vitro CCR2 and CCR5 Receptor Affinity Studies of Cenicriviroc Mesylate CVC (TBR-652), Maraviroc (MVC) or BMS-22, on Murine Blood and Splenic Monocytes (Study Number 652-9-1024). 2015.
31. Hayashi H, Sakai T. Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol. 2011; 300: G729-G738. doi: 10.1152/ajpgi.00013.2011 PMID: 21350186
32. Ucero AC, Benito-Martin A, Izquierdo MC, Sanchez-Niño MD, Sanz AB, Ramos AM, et al. Unilateral ureteral obstruction: beyond obstruction. Int Urol Nephrol. 2014; 46: 765-776. doi: 10.1007/s11255-013-0520-1 PMID: 24072452
33. Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2013; 14: 11963-11980. doi: 10.3390/ijms140611963 PMID: 23739675
34. Henderson RB, Hobbs JA, Mathies M, Hogg N. Rapid recruitment of inflammatory monocytes is independent of neutrophil migration. Blood. 2003; 102: 328-335. PMID: 12623845
35. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012; 367: 135-145. doi: 10.1056/NEJMoa1201248 PMID: 22784116
36. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013; 8: e75361. doi: 10.1371/journal.pone.0075361 PMID: 24130706
37. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013; 46: 141-152. doi: 10.1007/s00795-013-0016-1 PMID: 23430399
38. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-1321. PMID: 15915461
39. Byron MM, D'Antoni ML, Premeaux T, Lefebvre E, Ndhlovu LC. Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes. J Immunol. 2015; 194: 187.8.
40. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014; 147: 577-594. doi: 10.1053/j.gastro.2014.06.043 PMID: 25066692
41. Krenkel O, Mossanen JC, Ergen C, Heymann F, Lefebvre E, Eulberg D, et al. CCR2+ infiltrating monocytes promote acetaminophen-induced acute liver injury - therapeutic implications of inhibiting CCR2 and CCL2. J Hepatol. 2015; 62: S206.
42. Krenkel O, Püngel T, Mossanen J, Ergen C, Heymann F, Lefebvre E, et al. Dual CCR2/CCR5 anatagonist cenicriviroc leads to potent and significant reduction in proinflammatory CCR2+ monocyte infiltration in experimental acute liver injury. Presented at: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015; 2015 Nov 17; San Francisco, CA, USA. 1756.
43. Puengel T, Krenkel O, Mossanen J, Longerich E, Lefebvre E, Trautwein C, et al. The dual CCR2/CCR5 antagonist cenicriviroc ameliorates steatohepatitis and fibrosis in vivo by inhibiting the infiltration of inflammatory monocytes into injured liver. J Hepatol. 64: s159-s182.
44. Thompson M, Chang W, Jenkins H, Flynt A, Gottwald M, Lefebvre E. Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks. Hepatology 2014; 60: 424A.
45. Sherman KE, Abdel-Hameed E, Rouster SD. CCR2/CCR5 antagonism with cenicriviroc decreases fibrosis scores in HIV-infected patients. Presented at: HEP DART 2015, Frontiers in Drug Development for Viral Hepatitis; 2015 Dec 6; Hawaii, USA.
46. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120: 1183-1192. PMID: 11266382
47. Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013; 28: 64-70. doi: 10.1111/jgh.12271 PMID: 24251707
48. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis - new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10: 627-636. doi: 10.1038/nrgastro.2013.149 PMID: 23958599
49. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997; 126: 137-145. PMID: 9005748
50. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385: 956-965. doi: 10.1016/S0140-6736(14)61933-4 PMID: 25468160
51. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-1685. doi: 10.1056/NEJMoa0907929 PMID: 20427778
52. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013; 58: 1941-1952. doi: 10.1002/hep.26461 PMID: 23703580
53. Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin. 2005; 26: 575-580. PMID: 15842776
54. Han JY, Kim YJ, Kim L, Choi SJ, Park IS, Kim JM, et al. PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. J Korean Med Sci. 2010; 25: 35-41. doi: 10.3346/jkms.2010.25.1.35 PMID: 20052345
55. Higashi K, Oda T, Kushiyama T, Hyodo T, Yamada M, Suzuki S, et al. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology (Carlton). 2010; 15: 327-335.
56. Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016; 150: 1147-1159. doi: 10.1053/j.gastro.2016.01.038 PMID: 26874076